Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
The European Journal of Health Economics
Erschienen in: The European Journal of Health Economics 2/2012

01.04.2012 | Original Paper

Cost-effectiveness of treatment with etanercept for psoriasis in Sweden

verfasst von: Christopher Knight, Josephine Mauskopf, Mats Ekelund, Amitabh Singh, Shiyi Yang, Robert Boggs

Erschienen in: The European Journal of Health Economics | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To estimate the cost-effectiveness, from a Swedish societal perspective, of intermittent use of etanercept (Enbrel) with interruptions of use after 24 weeks compared to continuous use of adalimumab (Humira) as well as non-systemic standard of care in patients with moderate to severe psoriasis.

Methods

A Markov decision-tree model was constructed from clinical trials results. Patients starting etanercept, adalimumab, or non-systemic therapy moved through the model’s 10-years horizon. Model input parameters included clinical response rates. Outcome measures included direct and indirect costs and quality-adjusted life-years (QALYs).

Results

The incremental total (direct and indirect) costs per QALY were 1,559,939 kr (€165,354) for adalimumab 40 mg every other week, compared with intermittent once-weekly Enbrel 50 mg, and 93,629 kr (€9,925) for once-weekly intermittent etanercept 50 mg compared with non-systemic standard of care.

Conclusions

This analysis showed that, with a 470,000 kr (€50,000) per QALY willingness-to-pay threshold, once-weekly etanercept 50 mg, used intermittently, is a cost-effective treatment for moderate to severe psoriasis compared with adalimumab and non-systemic standard of care.
Literatur
1.
Christophers, E.: Psoriasis epidemiology and clinical spectrum. Clin. Exp. Dermatol 26(4), 314–320 (2001)PubMedCrossRef
2.
Langley, R.G.B., Krueger, G.G., Griffiths, C.E.M.: Psoriasis: epidemiology, clinical features, and quality of life. Ann. Rheum. Dis 64, 18–23 (2005)CrossRef
3.
Devrimci-Ozguven, H., Kundakci, N., Kumbasar, H., Boyvat, A.: The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J. Eur. Acad. Dermatol. Venereol 14, 267–271 (2000)PubMedCrossRef
4.
Ginsburg, I.H., Link, B.G.: Feelings of stigmatization in patients with psoriasis. J. Am. Acad. Dermatol 20, 53–63 (1989)PubMedCrossRef
5.
Vardy, D., Besser, A., Amir, M., Gesthalter, B., Biton, A., Buskila, D.: Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br. J. Dermatol 147, 736–742 (2002)PubMedCrossRef
6.
Richards, H.L., Fortune, D.G., Main, C.J., Griffiths, C.E.: Stigmatization and psoriasis. Br. J. Dermatol 149, 209–210 (2003)PubMedCrossRef
7.
Finzi, A.F., Mantovani, L.G., Belisari, A., Italian Association for Studies on Psoriasis: The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. Associazione Italiana Studi Psoriasi. J. Eur. Acad. Dermatol. Venereol 15(4), 320–324 (2001)PubMed
8.
Kugland, B., Ehlken, B., Hofmaier, A., Augustin, M., Berger, K.: Cost-of-illness study in patients suffering from chronic plaque psoriasis in Germany. PSN 8. Presented at the 6th annual European congress of international society for pharmacoeconomics and outcomes research (ISPOR). Value Health. 6(6), 786 (2003)
9.
Berger, K., Ehlken, B., Kugland, B., Augustin, M.: Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J. der Deutschen Dermatologischen Gesellschaft 3(7), 511–518 (2005)CrossRef
10.
Finlay, A.Y., Coles, E.C.: The effect of severe psoriasis on the quality of life of 369 patients. Br. J. Dermatol 132(2), 236–244 (1995)PubMedCrossRef
11.
Lebwohl, M., Ali, S.: Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J. Am. Acad. Dermatol 45(4), 487–498 (2001)PubMedCrossRef
12.
Lebwohl, M., Ali, S.: Treatment of psoriasis. Part 2. Systemic therapies. J. Am. Acad. Dermatol 45(5), 649–661 (2001)PubMedCrossRef
13.
Shikiar, R., Heffernan, M., Langley, R.G., Willian, M.K., Okun, M.M., Revicki, D.A.: Humira® treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J. Dermatol. Treat 18(1), 25–31 (2007)CrossRef
14.
Gordon, K.B., Langley, R.G., Leonardi, C., Toth, D., Menter, M.A., Kang, S., et al.: Clinical response to adalimumab in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol 55, 598–606 (2006)PubMedCrossRef
15.
Saurat, J., Stingl, G., Dubertret, L., Papp, K., Langley, R.G., Ortonne, J., et al.: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol 158, 558–566 (2008)PubMedCrossRef
16.
Menter, A., Tyring, S.K., Gordon, K., Kimball, A.B., Leonardi, C.L., Langley, R.G., et al.: Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J. Am. Acad. Dermatol 58, 106–115 (2008)PubMedCrossRef
17.
Papp, K., Leonard, C., Gordon, K., Okun, M.: Efficacy and safety of adalimumab in a 120-weeks open-label study in patients with moderate to severe chronic plaque psoriasis. P2777. Presented at the 65th annual meeting of the American Academy of Dermatology (2007)
18.
Gordon, K.B., Gottlieb, A.B., Loenardi, C.L., Elewski, B.E., Wang, A., Jahreis, A., for the etanercept psoriasis study group, et al.: Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J. Dermatol. Treat 17, 9–17 (2006)CrossRef
19.
Papp, K.A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C.E.M., Nakanishi, A.M., Zitnik, R., van de Kerkhof, P.C.M., for the Etanercept Psoriasis Study Group: A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol 152, 1304–1312 (2005)PubMedCrossRef
20.
Leonardi, C.L., Powers, J.L., Matheson, R.T., Goffe, B.S., Zitnik, R., Wang, A., Gottlieb, A.B., Etanercept Psoriasis Study Group: Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med 349(21), 2014–2022 (2003)PubMedCrossRef
21.
van de Kerkhof, P.C.M., Segaert, S., Lahfa, M., Luger, T.A., Karolyi, Z., Kaszuba, A., et al.: Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br. J. Dermatol 159, 1177–1185 (2008)PubMed
22.
Finlay, A.Y.: Current severe psoriasis and the rule of tens. Br. J. Dermatol 152, 861–867 (2005)PubMedCrossRef
23.
24.
25.
26.
27.
Ds 2002:49 Den svenska sjukan—sjukfrånvaron i åtta olika länder
28.
29.
30.
Tennvall, G.R., Bergman, A., Bjarnason, A., Hjelmgren, J., Hjortsberg, C., Svensson, A.: Behandlingsmönster, resursanvändning, kostnader och livskvalitet relaterat till psoriasis—Resultat från en svensk patientenkät och journalgenomgång. Studien presenteras på Svenska Läkaresällskapets Riksstämma i Stockholm (2009)
31.
Newcombe, R.G.: Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat. Med 17, 857–872 (1998)PubMedCrossRef
32.
Wilson, E.B.: Probable inference, the law of succession, and statistical inference. J. Am. Stat. Assoc 22, 209–221 (1927)CrossRef
33.
Briggs, A.H., Ades, A.E., Price, M.J.: Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med. Decis. Mak 23, 341–350 (2003)CrossRef
34.
Woolacott, N., Bravo, V.Y., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K., et al.: Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol. Assess 10(31), iii–iv, xiii–xvi, 1–239 (2006)
35.
Gospodarevskaya, E., Picot, J., Cooper, K., Loveman, E., Takeda, K.: Ustekinumab for the treatment of moderate to severe psoriasis. Health Technol. Assess 13, 61–66 (2009)PubMed
36.
37.
38.
Papp, K., Parish, L.C., Gu, Y., Goldblum, O., Okun, M.: Efficacy Outcomes for Patients with Psoriasis who Interrupt Adalimumab Therapy. Presented at European Academy of Dermatology and Venereology, Paris (2008)
39.
Patel, V., Horn, E.J., Lobosco, S.J., Fox, K.M., Stevens, S.R., Lebwohl, M.: Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J. Am. Acad. Dermatol 58, 964–969 (2008)PubMedCrossRef
40.
Leonardi, C.L., Elewski, B.E., Camisa, C., Wang, A.T., Zitnik, R.J.: The efficacy and safety of etanercept in the retreatment of psoriasis after relapse. In: Proceedings of the American Academy of Dermatology, Jul–Aug, New York (2004)
41.
Fleischmann, R., Stern, R., Iqbal, I.: Etanercept-review of efficacy and safety after five years of clinical use. Therapy 1(1), 11–23 (2004)
42.
Patel, T., Gordon, K.B.: Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol. Therapy 17, 427–431 (2004)CrossRef
43.
Raychaudhuri, S.P., Nguyen, C.T., Raychaudhuri, S.K., Gershwin, M.E.: Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun. Rev 9, 67–81 (2009)PubMedCrossRef
44.
Xavier Lymphoma, rheumatoid arthritis, and TNF-alpha antagonists (editorial). Jt. Bone Spine (in press)
45.
Krueger, G.G., Elewski, B., Papp, K., Wang, A., Zitnik, R., Jahreis, A.: Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J. Am. Acad. Dermatol 54, S112–S119 (2006)PubMedCrossRef
46.
Lloyd, A., Reeves, P., Conway, P., Reynolds, A., Baxter, G.: Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br. J. Dermatol 160, 380–386 (2009)PubMedCrossRef
47.
Nelson, A.A., Pearce, D.J., Fleischer, A.B., Balkrishnan, R., Feldman, S.R.: Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-weeks treatment period. J. Am. Acad. Dermatol 58, 125–135 (2008)PubMedCrossRef
48.
Sizto, S., Bansback, N., Feldman, S.R., Willian, M.K., Anis, A.H.: Economic evaluation of systemic therapies for moderate to severe psoriasis. Br. J. Dermatol. Epub (2008)
Metadaten
Titel
Cost-effectiveness of treatment with etanercept for psoriasis in Sweden
verfasst von
Christopher Knight
Josephine Mauskopf
Mats Ekelund
Amitabh Singh
Shiyi Yang
Robert Boggs
Publikationsdatum
01.04.2012
Verlag
Springer-Verlag
Erschienen in
The European Journal of Health Economics / Ausgabe 2/2012
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-010-0293-8

Weitere Artikel der Ausgabe 2/2012

The European Journal of Health Economics 2/2012 Zur Ausgabe

Original Paper

Defining care products to finance health care in the Netherlands

Original Paper

Decision-making in general practice: the effect of financial incentives on the use of laboratory analyses

Editorial

Separating the wheat from the chaff

Original Paper

Malpractice liability, technology choice and negative defensive medicine

Original Paper

Exploring the disparities of regional health care expenditures in Switzerland: some empirical evidence

Original Paper

Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam